Success Metrics

Clinical Success Rate
66.7%

Based on 10 completed trials

Completion Rate
67%(10/15)
Active Trials
14(44%)
Results Posted
130%(13 trials)
Terminated
5(16%)

Phase Distribution

Ph phase_2
12
38%
Ph phase_4
1
3%
Ph not_applicable
1
3%
Ph phase_1
8
25%
Ph phase_3
10
31%

Phase Distribution

8

Early Stage

12

Mid Stage

11

Late Stage

Phase Distribution32 total trials
Phase 1Safety & dosage
8(25.0%)
Phase 2Efficacy & side effects
12(37.5%)
Phase 3Large-scale testing
10(31.3%)
Phase 4Post-market surveillance
1(3.1%)
N/ANon-phased studies
1(3.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

62.5%

10 of 16 finished

Non-Completion Rate

37.5%

6 ended early

Currently Active

14

trials recruiting

Total Trials

32

all time

Status Distribution
Active(16)
Completed(10)
Terminated(6)

Detailed Status

Recruiting14
Completed10
Terminated5
Not yet recruiting2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
32
Active
14
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Phase 18 (25.0%)
Phase 212 (37.5%)
Phase 310 (31.3%)
Phase 41 (3.1%)
N/A1 (3.1%)

Trials by Status

withdrawn13%
terminated516%
not_yet_recruiting26%
recruiting1444%
completed1031%

Recent Activity

Clinical Trials (32)

Showing 20 of 32 trialsScroll for more
NCT06843447Phase 1

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

Recruiting
NCT06780111Phase 1

Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

Recruiting
NCT06966700Phase 3

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Recruiting
NCT06637423Phase 1

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

Recruiting
NCT06841354Phase 3

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Recruiting
NCT07405151Phase 1

A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)

Recruiting
NCT06717347Phase 3

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Recruiting
NCT06890884Phase 2

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Recruiting
NCT06925737Phase 3

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

Recruiting
NCT06863272Phase 1

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

Recruiting
NCT06780098Phase 2

Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)

Recruiting
NCT06312137Phase 3

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Recruiting
NCT07232602Phase 1

KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)

Recruiting
NCT05776927Phase 3

A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.

Not Yet Recruiting
NCT06428409Phase 1

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

Recruiting
NCT07166666Not Applicable

Study Comparing Atomizerd Midazolam & Fentanyl and Dexmedomidine for Procedural Sedation in Adult and Pediatric Patient (2 to 60 Years Old)

Not Yet Recruiting
NCT01244815Phase 3

Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P06107 Has an Extension [P05898; NCT01349907])(P06107)

Completed
NCT01349907Phase 3

Extension Study of Asenapine [P06107 (NCT01244815)] for Pediatric Bipolar Disorder (P05898)

Completed
NCT03250689Phase 2

Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps (NETs) in Chronic Obstructive Pulmonary Disease (COPD)

Terminated
NCT03034967Phase 2

Danirixin Dose Ranging Study in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Completed

Drug Details

Intervention Type
DRUG
Total Trials
32